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A 71-year-old man suffered from diabetic vitreous hemorrhage in his left pseudophakic eye. He received
20-gauge pars plana vitrectomy and removal of taut posterior hyaloid traction in June 2011. Spectral-
domain optical coherence tomography demonstrated cystoid macular edema 1 month after the opera-
tion. The macular edema did not respond to macular grid laser. Intravitreal bevacizumab (1.25 mg) was
injected, which was effective for managing diabetic macular edema initially. The edema recurred 3
months following the bevacizumab injection. Subsequent intravitreal triamcinolone 1 mg also failed to
treat the macular edema. Ozurdex, a dexamethasone implant, was injected intravitreally in January 2012.
The central foveal thickness decreased, and visual acuity improved. The effect persisted for 6 months.
There was no systemic or ocular adverse event during the follow-up period. This intravitreal dexa-
methasone implant could be helpful for diabetic macular edema in vitrectomized eyes.
Copyright  2013, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Diabetic retinopathy is a common and speciﬁc microvascular
complication of diabetes mellitus.1 Diabetic macular edema (DME) is
a manifestation of diabetic retinopathy that produces loss of central
vision and is now the most common cause of moderate vision loss
in diabetic patients.2 The pathophysiology of DME involves both the
presence of inﬂammation and angiogenic stimulant regarding
vascular endothelial growth factor (VEGF).2 Corticosteroid treatment
has been shown to have a beneﬁcial effect on DME.3 The probable
mechanisms involved are an increase in tight-junction proteins that
diminishes vessel leakage by anti-inﬂammatory activity, and angio-
static properties through inhibition of VEGF.4
Dexamethasone is a potent corticosteroid. The Ozurdex (Aller-
gan, Inc., Irvine, CA, USA), intravitreal dexamethasone implant
consists of a biodegradable copolymer of polylactic-co-glycolic acid
containing micronized dexamethasone 0.7 mg. It was developed
to deliver sustained levels of preservative-free dexamethasone.this article.
ology, Far Eastern Memorial
District, New Taipei City 220,
ng).
e Ophthalmologic Society of TaiwOzurdex has been approved for treatment of macular edema after
retinal vein occlusion and noninfectious uveitis by the Food and
Drug Administration in the USA.5,6 This dexamethasone implant
has been shown to be effective in the treatment of DME.7e9
In this article, we report the effect and safety proﬁle of single
intravitreal dexamethasone implant in a vitrectomized eye with
diabetic macular edema. A literature review indicates that this is
the ﬁrst case report in Taiwan.2. Case report
A 71-year-old man had type 2 diabetes mellitus that was under
regular medical control. He suffered from severe nonproliferative
diabetic retinopathy and underwent panretinal laser photocoagu-
lation in both eyes. Subsequent phacoemulsiﬁcations and foldable
acrylic intraocular lens-in-the-bag insertions were also performed
in both eyes. Vitreous hemorrhage and taut posterior hyaloid
traction occurred 3 months after the cataract operation in the left
eye. He received conventional 20-gauge pars plana vitrectomy
(Accurus; Alcon Laboratories Inc., Fort Worth, TX, USA), removal of
adherent posterior hyaloid surface on the surface of the retina,
supplement retinal photocoagulation using diode laser (Iris Medi-
cal Instruments, Mountain View, CA, USA), and placement of 15%
C3F8 in June, 2011. We added cryotherapy of the anterior retina andan. Published by Elsevier Taiwan LLC. All rights reserved.
T.-H. Chen et al. / Taiwan Journal of Ophthalmology 3 (2013) 163e167164sclerotomy sites (Mira, Uxbridge, MA, USA) at the end of the sur-
gery, because a prior randomized study concluded that the proce-
dure was helpful for inhibition of ﬁbrovascular ingrowth near
vitreous base and sclerotomies and prevention of recurrent vitre-
ous hemorrhage after diabetic vitrectomy.10 Spectral-domain op-
tical coherence tomography (RTVue; Optovue, Fremont, CA, USA)
revealed cystoid macular edema; central foveal thickness (CFT) in
the central 1-mm area was 541 mm (Fig. 1A). His best-corrected
visual acuity (BCVA) was 20/800. There was no focal leaking
microaneurysm within the macula. Macular grid pattern double-
frequency yttriumealuminumegarnet laser (Alcon Laboratories
Inc.) was administered according to the protocol previously
described.11 The macular edema did not respond to macular laser
photocoagulation.
Intravitreal bevacizumab (Genentech, San Francisco, CA, USA)
1.25 mg was administered to manage the macular edema in August
2011. The CFT decreased to 372 mm, but some cystoid change per-
sisted 1 month following the injection (Fig. 1B). His BCVA improved
to 20/100. Three months after the bevacizumab injection, macular
edema recurred (Fig. 1C). The BCVA deteriorated to 20/200, and the
CFT became 418 mm. The patient refused to undergo subsequent
intravitreal bevacizumab because he subjectively did not feel
improvement of vision. Intravitreal triamcinolone 1 mg (Kenacort;Fig. 1. Spectral-domain optical coherence tomography shows: (A) severe macular edema
bevacizumab; and (C) macular edema recurrence 3 months after intravitreal bevacizumab.Kitazawa Inc, Taipei, Taiwan) was injected subsequently. The edema
persisted. His BCVA was 20/200, and the CFT was 424 mm at the 1-
month follow-up examination (Fig. 2A).
A dexamethasone implant was injected intravitreally in January
2012. The patient was prepared in the operating room. We used
proparacaine drops as topical anesthesia and subconjunctival in-
jection of 2% lidocaine into the temporal lower quadrant. The skin
and conjunctival sac was disinfected by povidoneeiodine. The cap
was carefully removed from the 22-gauge applicator. The safety tab
was pulled straight off the applicator. The long axis of the applicator
was held parallel to the limbus, and the sclera was engaged at an
oblique angle with the bevel of the needle 3.5 mm away from the
limbus. The needle tip was advanced within the sclera for about
1 mm, then redirected towards the center of the eye and advanced
until penetration of sclera was completed and the vitreous cavity
was entered. The actuator button was slowly depressed until an
audible click was noted, and the needle was then removed. The
tetracycline ointment was placed into the conjunctival sac. The eye
was patched for 1 day. There were no cells and ﬂares in the anterior
chamber and vitreous cavity, and the Ozurdex implant was seen
in the inferior part of vitreous cavity (Fig. 3). The patient was
instructed to instill one drop of 0.3% norﬂoxacin into the injected
eye four times daily for 3 weeks.with cystic change; (B) macular edema partial subsidance 1 month after intravitreal
Fig. 2. Spectral-domain optical coherence tomography shows: (A) macular edema with cystic change persists 1 month after intravitreal triamcinolone acetonide; (B) macular
edema completely resolved 1 month following intravitreal Ozurdex; (C) macular edema improving 3 months following Ozurdex injection; and (D) macular edema with cystic
change recurrence 6 months after Ozurdex injection.
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and 320 mm, and his BCVA improved to 20/50, 20/50, 20/60, 20/60,
20/100, and 20/100 at 1 month, 2 months, 3 months, 4 months, 5
months, and 6 months, respectively, following the injection
(Fig. 2BeD), respectively. However, some cystic changes were
observed after 4 months. Intraocular pressure (IOP) was normal
both prior to and after the injections. There were no local compli-
cations, such as sterile endophthalmitis, elevated intraocular
pressure, or systemic effect, noted during the follow-up period.
3. Discussion
Several treatments have been proposed for DME. Conventional
treatment mainly involves macular laser photocoagulation.3,11
Triamcinolone, a long-acting corticosteroid, has an anti-
inﬂammatory effect. A systematic review of four randomized
controlled trials for refractory DME treated by intravitrealtriamcinolone 4 mg demonstrated that triamcinolone injectionwas
more effective than placebo for visual improvement at 3 months,
but the beneﬁt was no longer signiﬁcant at 6 months.12 Another
randomized trial found that there was an initial beneﬁcial effect of
intravitreal triamcinolone 4 mg on patients with DME at 4 months
compared with a 1-mg dose or with macular laser.3 However, the
beneﬁt diminished thereafter and, at 3 years, anatomical and
functional results were better in the laser group than in the
triamcinolone groups (1 mg and 4 mg, respectively).3 Some of pa-
tients did not respond to either macular laser or triamcinolone.3
Both triamcinolone doses, especially the 4-mg dose, were associ-
ated with an increased incidence of elevated IOP.3
Bevacizumab is a full-length recombinant humanized mono-
clonal antibody directed against the VEGF. Intravitreal bevacizumab
is employed to lower the intraocular VEGF level, and has been
found to reduce DME temporarily.1,4 A multicenter study showed
that repeated intravitreal bevacizumab 1.25 mg signiﬁcantly
Fig. 3. The dexamethasone implant observed in the vitreous cavity on the next day
after injection.
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months.4
Dexamethasone is a potent corticosteroid, with six-times more
anti-inﬂammatory activity than triamcinolone. However, the short
intraocular half-life of dexamethasone makes this approach difﬁ-
cult for clinical use. The dexamethasone implant can maintain the
intravitreal therapeutic level by sustained release of the drug for 6
months without retinal toxicity after a single injection.5 In a ran-
domized clinical study, Ozurdex injection demonstrated superior
anatomical and functional outcomes in macular edema of patients
with branch or central retinal vein occlusion than the sham group
in a 12-month interval.5 The most common adverse reaction is
elevation of IOP. Nearly 32% of eyes in the prior study had at least a
10-mmHg increase in IOP. Intravitreal dexamethasone implant has
been shown to be beneﬁcial in the treatment of DME.7e9 A case
series study collected nine eyes with persistent DME undergoing
intravitreal injection of anti-VEGF, corticosteroids, or macular
laser.7 Following Ozurdex injections, improvement in visual acuity
and macular thickness was found in the ﬁrst days after the
administration. Such improvementwasmaintained until the fourth
month.7 Another study included 18 eyes with recalcitrant DME
receiving prior macular laser and/or intravitreal anti-VEGF in-
jections.9 An increase of visual acuity and a decrease of macular
thickness were noted from 1 month to 4 months after intravitreal
dexamethasone implant.9
Drug diffusion and clearance from the vitreous cavity is more
rapid in vitrectomized eyes, limiting drug exposure to the retina
and reducing treatment success and options.8 Intravitreal phar-
macologic treatment of posterior segment disease may be less
effective in vitrectomized eyes. Studies in monkeys have shown
that the vitreous half-life of bevacizumab is shorter in vitrectom-
ized eyes compared with nonvitrectomized eyes.13 Studies in rab-
bits have also revealed that intravitreal triamcinolone decreases
more rapidly in the vitrectomized eye than in the nonvitrectomized
eye.14 Vitrectomy has also been shown to affect the intraocular
concentration of triamcinolone after intravitreal injection in hu-
man eyes: elimination of triamcinolone from the aqueous humor
after a single intravitreal injection was accelerated in a vitrectom-
ized patient compared with nonvitrectomized patients.15 In a hu-
man study, 3-monthly intravitreal bevacizumab had no effect on 11
vitrectomized eyes with DME.16 The authors suggested that the lack
of efﬁcacy of bevacizumab might be related to faster clearance and
subtherapeutic concentrations of bevacizumab in vitrectomized
eyes.16 Sustained-release delivery with the dexamethasone implantcan maintain the vitreous concentration over time to a similar
extent in vitrectomized and nonvitrectomized eyes of rabbits.17 A
multicenter study enrolled 55 vitrectomized eyes with DME un-
dergoing prior anti-VEGF, triamcinolone, or macular laser therapy.8
Treatment with dexamethasone intravitreal implant led to statis-
tically and clinically signiﬁcant improvements in both vision and
vascular leakage for 6 months.8 Increases of IOP was found in 17% of
study eyes, initiating temporary medical control. No patient
required a laser or surgical procedure to control IOP.8
In the present case, macular laser was not helpful to treat DME.
Two prior randomized studies discovered that the maximal effect
occurred at 1 month after intravitreal triamcinolone for DME in
visual improvement and macular thickness reduction.18,19 Our pa-
tient failed to respond to intravitreal triamcinolone either
anatomically or functionally at 1month and 2months following the
injection. The subsequent visual improvement after intravitreal
Ozurdex cannot be due to triamcinolone.We used intravitreal 1-mg
triamcinolone rather than standard 4-mg dose for the edema in
order to avoid postinjection ocular hypertension. In spite of the lack
of an IOP rise, the failure of triamcinolone might be due to the low
dose or to faster clearance of the drug in this vitrectomized eye.
Comparing the results 1 month following the treatments, visual
acuity improved by one and three lines in the Snellen chart, CFT
decreased to 372 mm with some cystoid changes and to 327 mm
with normal macular contour after intravitreal bevacizumab and
the dexamethasone implant. The macular edema recurred 3
months and 6 months after intravitreal bevacizumab and the
dexamethasone implant. The macular edema showed better and
longer response in dexamethasone implant than in bevacizumab.
These observations might be associated with accelerated elimina-
tion and suboptimal intravitreal concentration of bevacizumab af-
ter the vitrectomy, and the property of slow release and
maintaining a therapeutic level in the dexamethasone implant.
In conclusion, a single intravitreal injection of Ozurdex was
effective for persistent DME over 6 months in a vitrectomized eye
receiving prior anti-VEGF, corticosteroids, and macular laser. There
was no systemic or ocular adverse event after the injection.References
1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376:124e36.
2. Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, et al. Vascular
endothelial growth factor is a critical stimulus for diabetic macular edema. Am J
Ophthalmol 2006;142:961e9.
3. Diabetic Retinopathy Clinical Research Network, Beck RW, Edwards AR,
Aiello LP, Bressler NM, Ferris F, et al. Three-year follow up of a randomized trial
comparing focal/grid photocoagulation and intravitreal triamcinolone for dia-
betic macular edema. Arch Ophthalmol 2009;127:245e51.
4. Arevalo JF, Sanchez JG, Wu L, Maia M, Alezzandrini AA, Brito M, et al. Primary
intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-
American Collaborative Retina Study Group at 24 Months. Ophthalmology
2009;116:1488e97.
5. Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J, et al.
Dexamethasone intravitreal implant in patients with macular edema related to
branch or central retinal vein occlusion: twelve-month study results.
Ophthalmology 2011;118:2453e60.
6. Lowder C, Belfort R, Lightman S, Foster CS, Robinson MR, Schiffman RM, et al.
Dexamethasone intravitreal implant for noninfectious intermediate or poste-
rior uveitis. Arch Ophthalmol 2011;129:545e53.
7. Zucchiatti I, Lattanzio R, Querques G, Querques L, Turco CD, Cascavilla ML, et al.
Intravitreal dexamethasone implant in patients with persistent diabetic mac-
ular edema. Ophthalmologica 2012;228:117e22.
8. Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh HY, Li XY, et al. Dexamethasone
intravitreal implant for treatment of diabetic macular edema in vitrectomized
patients. Retina 2011;31:915e23.
9. Rishi P, Rishi E, Kuniyal L, Mathur G. Short-term results of intravitreal dexa-
methasone implant (OZURDEX_) in treatment of recalcitrant diabetic macular
edema: a case series. Oman J Ophthalmol 2012;5:79e82.
10. Yeh PT, Yang CM, Yang CH, Huang JS. Cryotherapy of the anterior retina
and sclerotomy sites in diabetic vitrectomy to prevent recurrent vitreous
hemorrhage: an ultrasound biomicroscopy study. Ophthalmology 2005;112:
2095e102.
T.-H. Chen et al. / Taiwan Journal of Ophthalmology 3 (2013) 163e167 16711. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation
for diabetic macular edema. Early treatment diabetic retinopathy study report
number 1. Arch Ophthalmol 1985;103:1796e806.
12. Yilmaz T, Weaver CD, Gallagher MJ, Cordero-Coma M, Cervantes-Castaneda RA,
Klisovic D, et al. Intravitreal triamcinolone acetonide injection for treatment of
refractory diabetic macular edema: a systematic review. Ophthalmology
2009;116:902e13.
13. Kakinoki M, Sawada O, Sawada T, Saishin Y, Kawamura H, Ohji M. Effect of
vitrectomy on aqueous VEGF concentration and pharmacokinetics of bev-
acizumab in macaque monkeys. Invest Ophthalmol Vis Sci 2012;53:5877e80.
14. Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal
triamcinolone acetonide between vitrectomized and nonvitrectomized eyes.
Retina 2005;25:556e60.
15. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters 3rd GB, Miller M. Intraocular con-
centration and pharmacokinetics of triamcinolone acetonide after a single
intravitreal injection. Ophthalmology 2003;110:681e6.16. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for dia-
betic macular edema in previously vitrectomized eyes. Am J Ophthalmol
2007;144:124e6.
17. Welty D, Kuppermann BD, Chang-lin JE. Dexamethasone posterior segment drug
delivery system: pharmacokinetics in vitrectomized and non-vitrectomized eyes.
Paper presented at 25th Annual Meeting of the American Society of Retina Spe-
cialists; 2007. Indian Wells, CA. Abstract 3597.
18. Cardillo JA, Melo Jr LA, Costa RA, Skaf M, Belfort Jr R, Souza-Filho AA, et al.
Comparison of intravitreal versus posterior sub-tenon’s capsule injection of
triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology
2005;112:1557e63.
19. Diabetic Retinopathy Clinical Research Network, Googe J, Brucker AJ,
Bressler NM, Qin H, Aiello LP, et al. Randomized trial evaluating short-term
effects of intravitreal ranibizumab or triamcinolone acetonide on macular
edema following focal/grid laser for diabetic macular edema in eyes also
receiving panretinal photocoagulation. Retina 2011;31:1009e27.
